Brief: Menarini Group & Newamsterdam Pharma Receive European Commission Approval For Ubeslo And Evlarco
21/09/2026 17:38
BRIEF-Menarini Group & Newamsterdam Pharma Receive European Commission Approval For Ubeslo And Evlarco Sept 21 (Reuters) - NewAmsterdam Pharma Company N.V. KH6.F:
MENARINI GROUP AND NEWAMSTERDAM PHARMA RECEIVE EUROPEAN COMMISSION APPROVAL FOR UBESLO® (OBICETRAPIB MONOTHERAPY) AND EVLARCO® (OBICETRAPIB PLUS EZETIMIBE FIXED-DOSE COMBINATION)
Source text: ID:nPreFkwDLa
Further company coverage: KH6.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on NewAmsterdam Pharma
See all newsBrief: Menarini Group & Newamsterdam Pharma Receive European Commission Approval For Ubeslo And Evlarco
Amgen falls after Novartis trial setback, BMO downgrade
Brief: Newamsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Newamsterdam Pharma Company N.V. - Announces Positive CHMP Opinion For Obicetrapib And Obicetrapib/Ezetimibe
Brief: NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)